Lung Cancer
A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression (TC greater than or equal to 50%) and Without Actionable Genomic Alterations (TROPION-Lung10) (D7632C00001)
- Details
ClinicalTrials.gov ID:
NCT06357533
Diagnosis Type:
NA
USOR Number:
- Address
,
P: